REG - Avacta Group PLC - AVA3996 data poster presentation at AACR

AvactaAnnouncement

27/03/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230327:nRSa2297Ua&default-theme=true

RNS Number : 2297U  Avacta Group PLC  27 March 2023

 

 

 

27 March 2023

 

Avacta Group plc

 

("Avacta" or the "Company" or, together with its subsidiary undertakings, the
"Group")

 

Avacta to present pre-clinical data on AVA3996 at the American Association for
Cancer Research Annual Meeting

 

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative,
targeted oncology drugs and powerful diagnostics, announces it will present a
poster entitled 'AVA3996, a novel pre|CISION™ medicine, targeted to the
tumor microenvironment via Fibroblast Activation Protein-alpha (FAP-a)
mediated cleavage', at the American Association for Cancer Research (AACR)
2023 Annual Meeting, taking place at Orange County Convention Center, Orlando,
Florida on 16 April.

 

The poster describes the data and pre-clinical rationale for the further
development and disease positioning of the Company's second pre|CISION™
candidate, AVA3996, a tumour microenvironment activated proteasome inhibitor.
AVA3996 utilises Avacta's pre|CISION™ platform to improve the therapeutic
index and therefore utility of proteasome inhibitors in tumours with high FAP
levels, including both solid and haematological tumours. AVA3996 has the
potential to deliver efficacious levels of the proteasome inhibitor warhead
directly to the tumour microenvironment while reducing systemic exposure and
hence associated toxicities, such as peripheral neuropathy.

 

Attending the conference from Avacta will be Fiona McLaughlin - Chief
Scientific Officer, Neil Bell - Chief Development Officer, David Jones - VP
Biology and Francis Wilson - VP Chemistry.

 Poster presentation Title     AVA3996, a novel pre|CISION™ medicine, targeted to the tumor
                               microenvironment via fibroblast activation protein-alpha (FAP-a) mediated
                               cleavage
 Session Category              Experimental and Molecular Therapeutics
 Session Title                 Targeting the Tumor Microenvironment
 Session Date and Time         Apr 16, 2023 1:30 PM - 5:30 PM ET
 Location                      Orange County Convention Center, Section 20
 Poster Board Number           17
 Abstract Presentation Number  583

 

 

The abstract is available via the AACR annual meeting website, here:
https://www.abstractsonline.com/pp8/#!/10828/presentation/2606
(https://www.abstractsonline.com/pp8/#!/10828/presentation/2606)

 

Copies of the poster will be available on Avacta's website following the
conference at: https://avacta.com/about/resources/posters/
(https://avacta.com/about/resources/posters/)

 

Alastair Smith, Avacta Chief Executive Officer, will provide a video
presentation overview for investors examining the data presented in the
poster. This will be available on 17(th) April at
https://avacta.com/investors/documents-presentations/
(https://avacta.com/investors/documents-presentations/) .

 

-Ends-

 

 

 

For further information from Avacta Group plc, please contact:

 

 Avacta Group plc                                                                Tel: +44 (0) 1904 21 7070

 Alastair Smith, Chief Executive Officer                                         www.avacta.com (http://www.avacta.com)

 Tony Gardiner, Chief Financial Officer

 Michael Vinegrad, Group Communications Director

 Stifel Nicolaus Europe Limited (Nomad and Broker)                               Tel: +44 (0) 207 710 7600

 Nicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland / Dhiren Suares   www.stifel.com (http://www.stifel.com/)
 / William Palmer-Brown

 FTI Consulting (Financial Media and IR)                                         Tel: +44(0) 203 727 1000

 Simon Conway / Alex Shaw / George Kendrick                                      Avacta.LS@fticonsulting.com (mailto:Avacta.LS@fticonsulting.com)

 Zyme Communications (Trade and Regional Media)                                  Tel: +44 (0)7891 477 378

 Lily Jeffery                                                                    lily.jeffery@zymecommunications.com

                                                                               (mailto:katie.odgaard@zymecommunications.com)

 

About Avacta Group plc - www.avacta.com (http://www.avacta.com)

 

Avacta Group plc is a life sciences company working to improve people's health
and well-being through innovative oncology drugs and powerful diagnostics.
Operating through two divisions, Diagnostics and Therapeutics, the Group's
mission is to provide professionals and consumers with solutions that improve
healthcare, fitness and well-being.

 

Avacta's Therapeutics Division, a clinical stage oncology drug innovator, is
building a wholly owned pipeline of novel Affimer(®) immunotherapies and
pre|CISION™ tumour targeted chemotherapies. This approach is designed to
address the lack of a durable response to current cancer immunotherapies
experienced by most patients and reduce the severe systemic toxicities caused
by chemotherapies. There are five programmes in the pipeline as well as
several global research collaborations and licensing partnerships. Avacta's
lead programme, AVA6000, is a pre|CISION™ tumour-targeted form of the
established chemotherapy doxorubicin. AVA6000 is in Phase I clinical trials in
patients with locally advanced or metastatic selected solid tumours.

 

The Affimer(®) platform is an alternative to antibodies that has been
designed to address many of the drawbacks of antibodies which, despite their
shortcomings, currently dominate the immuno-diagnostics and
immuno-therapeutics markets.

 

The pre|CISION™ tumour targeting platform can be used to modify a
chemotherapy in order to selectively release the active drug in tumour tissue
thereby reducing the systemic exposure that causes damage to healthy tissues.
pre|CISION™ modified chemotherapies are designed to reduce the side effects
and improve the overall safety and therapeutic potential of these powerful
anti-cancer treatments.

 

Avacta's Diagnostics Division develops and supplies a broad range of in-vitro
diagnostic (IVD) solutions. The Division is growing rapidly through an M&A
strategy to deliver a global scale IVD business providing market leading
solutions for healthcare professionals and consumers to inform treatment and
monitor health and well-being. In October 2022, Avacta acquired Launch
Diagnostics which serves the hospital pathology laboratory market in the UK
and Europe. Avacta Diagnostic's research and development centre in Wetherby,
UK uses its proprietary Affimer(®) platform to differentiate immunodiagnostic
products to provide marketing leading performance.

 

To register for news alerts by email go to
www.avacta.com/investor-news-email-alerts
(http://www.avacta.com/investor-news-email-alerts)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBRGDXIGDDGXL